E Fund Management Co. Ltd. Acquires Shares of 28,589 Structure Therapeutics Inc. (NASDAQ:GPCR)

E Fund Management Co. Ltd. bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 28,589 shares of the company's stock, valued at approximately $1,165,000. E Fund Management Co. Ltd. owned 0.06% of Structure Therapeutics as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. M&T Bank Corp acquired a new position in Structure Therapeutics during the fourth quarter worth $596,000. Natixis Advisors L.P. acquired a new stake in shares of Structure Therapeutics in the 4th quarter worth about $634,000. Russell Investments Group Ltd. acquired a new stake in shares of Structure Therapeutics in the 4th quarter worth about $1,157,000. New York State Common Retirement Fund acquired a new position in Structure Therapeutics during the 4th quarter valued at about $277,000. Finally, Federated Hermes Inc. increased its holdings in Structure Therapeutics by 104.2% during the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company's stock worth $92,411,000 after purchasing an additional 1,157,006 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Trading Down 1.5 %

Shares of GPCR traded down $0.57 on Thursday, reaching $38.65. 272,978 shares of the company's stock traded hands, compared to its average volume of 560,431. The stock's 50 day simple moving average is $39.15 and its two-hundred day simple moving average is $46.25. The stock has a market cap of $1.80 billion and a PE ratio of -47.25. Structure Therapeutics Inc. has a 52-week low of $21.79 and a 52-week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. Analysts forecast that Structure Therapeutics Inc. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Friday, May 3rd. Lifesci Capital reaffirmed an "outperform" rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $85.71.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.